1. A pharmaceutical composition comprising:! carboxyvinyl polymer and povidone polymer； and! a destabilizing agent, which usually has a destabilizing effect on the carboxyvinyl polymer, where the povidone polymer reduces the destabilizing effect. ! 2. The pharmaceutical composition of claim 1, wherein the destabilizing agent comprises a drug and a carboxyvinyl polymer and a povidone polymer are part of a pharmaceutical carrier for the drug. ! 3. The pharmaceutical composition according to claim 2, in which the drug includes moxifloxacin. ! 4. The pharmaceutical composition according to claim 2, in which the drug comprises one or more amino-functional groups and the destabilizing effect is the lack of solubility caused by the drug, which complexes with the carboxyvinyl polymer, with the formation of the drug / carboxyvinyl polymer complex, and in which the povidone polymer helps solubilize the drug / carboxyvinyl polymer complex. ! 5. The pharmaceutical composition according to any one of claims 1 to 4, where the pharmaceutical composition or its pharmaceutical carrier is a gel. ! 6. The pharmaceutical composition according to any one of claims 1 to 4, where the pharmaceutical composition is an ophthalmic composition that includes water and has a physiologically compatible pH. ! 7. The pharmaceutical composition according to any one of claims 1 to 4, where the composition is contained in a container that releases drops of the composition in a manner suitable for topical application to the eyes. !eight. The pharmaceutical composition according to any one of claims 1 to 4, where1. Фармацевтическая композиция, содержащая: ! карбоксивиниловый полимер и повидоновый полимер； и ! дестабилизирующее средство, которое обычно обладает дестабилизирующим эффектом на карбоксивиниловый полимер, где повидоновый полимер снижает дестабилизирующий эффект. !2. Фармацевтическая композиция по п.1, где дестабилизирующее средство включает лекарственное средство и карбоксивиниловый полимер
